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To date, there have been several systematic reviews with meta-analysis that have 
shown no reduction in mortality with the use of inhaled nitric oxide (iNO) in patients with 
acute respiratory distress syndrome (ARDS). Importantly, these reports fail to make a 
distinction between the pediatric and adult patient. The number of adult patients in these 
reviews are far greater than the number of pediatric patients, which makes it difficult to 
interpret the data regarding the role of iNO on the pediatric population. Extrapolating 
data from the adult population to the pediatric population is complicated as we know 
that physiology and the body’s response to disease can be different between adult and 
pediatric patients. iNO has been demonstrated to improve outcomes in term and near-
term infants with hypoxic respiratory failure associated with pulmonary hypertension. 
Recently, Bronicki et al. published a prospective randomized control trial investigating 
the impact of iNO on the pediatric patient population with acute respiratory failure. In this 
study, a benefit of decreased duration of mechanical ventilation and an increased rate 
of ECMO-free survival was demonstrated in patients who were randomized to receiving 
iNO, suggesting that there may be benefit to the use of iNO in pediatric ARDS (PARDS) 
that has not been demonstrated in adults. iNO has repeatedly been shown to transiently 
improve oxygenation in all age groups, and yet neonates and pediatric patients have 
shown improvement in other outcomes that have not been seen in adults. The mech-
anism that explains improvement with the use of iNO in these patient populations are 
not well understood but does not appear to be solely a result of sustained improvement 
in oxygenation. There are physiologic studies that suggest alternative mechanisms 
for explaining the positive effects of iNO, such as platelet aggregation inhibition and 
reduction in systemic inflammation. Hence, the role of iNO by various mechanisms and 
in various age groups warrants further investigation.
Keywords: pediatric acute respiratory distress syndrome, inhaled nitric oxide, pulmonary hypertension, 
mechanisms of action, clinical trials
iNTRODUCTiON
In many review articles of acute respiratory distress syndrome (ARDS), the conclusion that the use 
of iNO does not reduce mortality continues to be perpetuated. Most often, the references for this 
conclusion are the systematic reviews with meta analysis by Adhikari et al. (1, 2) and Afshari et al. 
(3) These are well conducted systematic reviews; however, the conclusion made from these studies 
as it pertains to pediatric ARDS (PARDS) could be challenged.
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Analysis of these influential systemic reviews reveals that 
the number of pediatric studies and overall number of pediatric 
patients are small. In fact, there are only three pediatric studies on 
this matter included. The number of pediatric studies are too few 
to determine the effect of iNO on PARDS outcome.
However, the extrapolation of this adult data to pediatrics has 
been widely accepted, and there has been inadequate investigation 
on the subject in pediatrics since these systematic reviews were 
published. Most have taken for granted that the answer regarding 
the benefit of iNO in PARDS exists when in fact the question as it 
applies to pediatrics has never scientifically been evaluated.
The other limitation to understanding the full impact of iNO 
has been the primary emphasis on its mechanism of action as a 
selective pulmonary vasodilator in improving V/Q matching and 
the outcome of mortality. Focusing on the effect of iNO by only 
this mechanism and this outcome may minimize its therapeutic 
importance. For example, Nitric oxide (NO) has a variety of 
effects on the immune system and immune regulation. This could 
be of particular interest in the context of ARDS, a disease whose 
pathology is largely a result of the immune response. Some stud-
ies in neonates have demonstrated that the incidence of chronic 
lung disease, a disease that results from an inflammatory process, 
could be attenuated with the use of iNO (4–6). These findings 
are important as they give evidence of the effects of iNO that we 
might be underestimating.
Until we have more pediatric specific data on ARDS and iNO, 
we are left reviewing what has been learned about ARDS, NO, 
and iNO from the laboratory and from adults. Equipped with the 
understanding that the pathology of ARDS and the response to 
ARDS are likely different between pediatrics and adults and that 
the mechanisms of iNO are diverse, pediatric practitioners should 
be challenging the notions that we have accepted from the adult 
data by re-examining the many properties of iNO and bringing 
new, important pediatric specific research to the forefront.
PATHOPHYSiOLOGY AND 
ePiDeMiOLOGY OF ARDS AND PARDS
One of the hallmarks of ARDS is hypoxemia. In this disease state, 
inflammation leads to injury of the pulmonary capillary endothe-
lium and the alveolar epithelium, which results in permeability 
and accumulation of polymorphonuclear cells, erythrocytes, 
platelets, and water in the airspaces (7). Pulmonary edema and 
inactivation of surfactant result in intrapulmonary shunting and 
thus hypoxemia.
One of the practice changing results from the ARDS Network 
study was the reduced mortality in adult patients with ARDS who 
were randomized to a low tidal volume ventilation strategy (8). The 
explanation for why mortality is significantly improved with lower 
tidal volume is not known, but one theory is the reduction in the 
inflammatory response induced by a lower tidal volume. Ranieri 
et al. found that patients with ARDS ventilated with a lower tidal 
volume had a decrease in inflammatory cells and cytokines in 
their BAL and plasma (9). The association between inflammation 
and tidal volume, or stretching of the respiratory system, became 
known as biotrauma (10). This concept emphasizes the significant 
role the immune system plays in the pathogenesis of ARDS.
Interestingly, although impaired oxygenation is a hallmark 
of the disease, therapies that have led to improved oxygenation, 
including iNO, have failed to show a significant reduction in mor-
tality outcome (11). Perhaps the lack of demonstrable mortality 
benefit is because patients with ARDS often die of multi-system 
organ failure (MSOF) rather than hypoxemia (12, 13). The pres-
ence of MSOF in ARDS is likely due to the host immune response. 
With damage to the alveolar-capillary barrier, inflammatory 
cells and cytokines can enter the general circulation and illicit a 
systemic inflammatory response than can lead to the impairment 
of multiple organs (14). In this scenerio, the lung becomes the 
source of inflammation and not solely the target of inflammation.
From an epidemiological standpoint, most studies show that 
ARDS is less common in children than in adults and that the 
mortality rate of children is less than adults (15). Sepsis is the 
most common risk factor in adults with concomitant MSOF as 
compared to children in whom pulmonary infections are the 
most common risk factor (16). And perhaps it is the increased 
MSOF in adults compared to children that explains the difference 
in mortality risk between these populations. This is an important 
distinction as we begin to further explore the potential therapeutic 
benefits of iNO and the possibility that there may be a difference 
on the impact on adults and children. As a lung-selective therapy, 
it has been thought that iNO is unlikely to improve overall survival 
when most adult patients dying from ARDS suffer from multiple 
organ failure (17). However, since children are more likely to have 
pneumonia than multi-organ failure, a lung-selective therapy, 
such as iNO, could provide more of a survival benefit in children 
than in adults.
Smith and colleagues provide a review of the pathophysiology 
of ARDS in children and adults (18). The point that the lungs are 
still developing and growing in children compared to adults is 
an important distinction emphasized in this paper, particularly 
because the response to infection and injury are likely different 
based on the milieu of growth factors, gene expression, and pro-
tein expression at various stages of lung development. They also 
emphasize that the innate immune response is different between 
children and adults. Infants have impaired clearance of the patho-
gen and less of the pro inflammatory response, which may be 
injurious to the lungs. In contrast, adults can clear the pathogen 
but suffer injury from the inflammatory response itself. The 
content of surfactant between patients with ARDS and PARDS is 
also different (19, 20), which may account for difference in benefit 
in the use of exogenous surfactant between children and adults 
with ARDS (21) and may also suggest that there is a difference in 
the injury to the alveolar epithelium between these groups.
Understanding the pathology of ARDS is important as it 
illustrates potential mechanisms for therapeutic interventions. 
Additionally, highlighting the differences between ARDS and 
PARDS, exemplifies that the disease state is not the same in all 
age groups, and hence the response to therapies, particularly iNO, 
may be different.
HiSTORY OF NO AND iNO
Since its discovery only a few decades ago, inhaled nitric oxide 
(iNO) has fascinated many in the field of critical care and 
3Hunt et al. Role of iNO in the Management of PARDS
Frontiers in Pediatrics | www.frontiersin.org August 2016 | Volume 4 | Article 74
medicine in general. Its potential benefits, limited evidence of 
proven benefit, but ongoing use as a rescue medication continue 
to be the focus of research and debate.
Nitric oxide gained much notoriety within the scientific 
community when it was declared the Molecule of the Year by 
Science in 1992. It was 6 years later that the individuals credited 
with its discovery, Ferid Murad, Robert Furchgott, and Louis 
Ignarro were awarded the Nobel prize for Physiology and 
Medicine in 1998.
In 1993, Rossaint et  al. published a landmark article in the 
New England Journal of Medicine that described the role of iNO 
in Acute Respiratory Distress Syndrome (ARDS) in reducing 
pulmonary artery pressures and increasing arterial oxygenation 
by improving V/Q mismatch without precipitating systemic 
hypotension (22).
Rossaint’s paper was followed by many important studies 
including several focused on the neonatal population, which 
showed definitive benefit of iNO in this patient population. 
In 1997, the Neonatal Inhaled Nitric Oxide Study Group 
(NINOS) showed that iNO was beneficial in full-term and 
nearly full-term infants with hypoxic respiratory failure by 
demonstrating that the use of iNO reduced the use of extra-
corporeal membrane oxygenation (ECMO) (23, 24). In 1998, 
the I-NO/PPHN study group showed that early use of iNO in 
term infants with persistent pulmonary hypertension (PPHN) 
had an acute and sustained improvement in oxygenation 
and a reduction in ECMO use that did not reach statistical 
significance (25).
In December 1999, The US Food and Drug Administration 
(FDA) approved the use of INOmax (nitric oxide) for inhalation 
for the treatment of “term and near-term (>34 weeks) neonates 
with hypoxic respiratory failure associated with clinical or 
echocardiographic evidence of pulmonary hypertension where 
it improves oxygenation and reduces the need for extracorporeal 
membrane oxygenation” (26). To date, this remains the only 
licensed indication for the use for iNO.
In August 2000, the American Academy of Pediatrics pub-
lished a statement on the conditions in which iNO should be 
used, which endorsed the FDA indications of the use of iNO for 
newborns with hypoxic respiratory failure (27).
The sole commercial manufacturer of INOmax at the 
time of FDA approval was INO Therapeutics. In March 2007, 
INO Therapeutics and Ikaria merged, and INOmax was 
then exclusively supplied by Ikaria until April of 2015, when 
Mallinckrodt Pharmaceuticals acquired Ikaria, Inc. Mallinckrodt 
Pharmaceuticals now maintains the many patents on the 
INOMAX drug label and INOMAX delivery system, five of 
which provide protection until 2029 and another five that provide 
protection until 2031.
MeCHANiSMS OF NO AND iNO
Nitric oxide is composed of two atoms that form a gaseous 
molecule. It is found naturally in the atmosphere and produced 
in various parts of the body. The enzyme nitric oxide synthase 
(NOS) converts l-arginine to nitric oxide. There are multiple 
isoforms of nitric oxide synthase (NOS). nNOS is the neuronal 
form that is involved in neurotransmission. iNOS is an inducible 
form involved in the immune response. eNOS is the endothelial 
nitric oxide synthase isoform, which is the form that is active in 
healthy vascular endothelial cells (28).
eNOS produces NO that acts specifically on endothelial 
smooth muscle cells. NO penetrates the cell membrane, which 
binds to the soluble guanylyl cyclase and activates it forming 
cGMP. cGMP binds to the cGMP-dependent protein kinase. The 
activated protein kinase then affixes to ionic channels of the cell 
membrane and the sarcoplasmic reticulum, which has the effect 
of decreasing the influx of calcium to the cell, increasing the ejec-
tion of calcium from the cell, sequestering the calcium within the 
sarcoplasmic reticulum, and decreasing calcium mobilization. 
The net effect of these reactions makes less calcium available for 
depolarization and contraction, which leads to smooth muscle 
relaxation (29).
With the understanding of NO’s ability to relax endothelial 
smooth muscle, multiple laboratory studies were performed to 
assess the effect of inhaled NO on the pulmonary vasculature 
(30, 31). In 1991, Frostell et  al. demonstrated in lamb models 
that iNO could produce pulmonary vasodilation by reversing 
hypoxic pulmonary vasoconstriction or thromboxane-induced 
pulmonary hypertension without causing systemic hypotension 
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(30). The mechanism similar to that of eNOS is the most likely 
explanation of how iNO leads to this effect. The inhaled NO 
is delivered directly to the pulmonary vascular endothelial 
cells causing the endothelial smooth muscle relaxation of the 
pulmonary vasculature. The pulmonary vasodilation reduces 
intrapulmonary shunting when lung disease is present, which 
allows for increased ventilation/perfusion (V/Q) matching and 
improved oxygenation.
Nitric oxide is known to have a multitude of other effects on 
various cells in the body as well. Yet, it is commonly believed that 
when delivered by inhalation, the effect of nitric oxide is limited 
to the lungs. As NO is exposed to the bloodstream, it binds rapidly 
and with a high affinity to hemoglobin, which then inactivates 
it (32). This is the explanation for why iNO leads to pulmonary 
vasodilation without causing significant systemic vasodilation 
or hypotension. It is worth noting, however, that there are some 
studies to suggest that NO bioactivity may actually reach distant 
organs even when delivered by inhalation. The implications of 
this is even less well understood that even further limits our true 
appreciation of the impact of iNO.
In addition to its effect on endothelial smooth muscle, NO 
also affects platelet activity. It has been observed in vitro that NO 
activates the guanylate cyclase inside platelets, which increases 
intraplatelet cGMP. The resulting activation of cGMP-dependent 
protein kinase here causes a reduction in fibrinogen biding to 
glycoprotein GP IIb/IIIa, which induces partial inhibition of 
platelet aggregation (33, 34).
Considering that activation and accumulation of platelets is 
observed in the alveolar tissues of patients with ARDS (35), and 
given the effect NO has on platelet aggregation, Samama et  al. 
investigated whether iNO could inhibit platelet aggregation in 
patients with ARDS (34). They found that the six patients studied 
showed a significant improvement in oxygenation, significant 
decrease in pulmonary artery pressure, and a significant decrease 
in ex vivo platelet aggregation after iNO administration without 
a change in their Ivy bleeding time. They concluded that the 
improvement in arterial oxygenation and pulmonary circulation 
are associated with a significant inhibition of platelet aggregation.
Nitric oxide has also been noted to have a number of potentially 
important effects on the immune system and has been implicated 
in a variety of mechanisms (36). NO has been shown to alter the 
balance between T helper (Th)1 and Th2 cells. In particular, NO 
decreases Th1 proliferation and IL-2 synthesis but increases IL-4 
synthesis from Th2 cells. By decreasing Th1 and increasing Th2 
responses, NO may inhibit the inflammatory response to viral 
and bacterial infections. Additionally, NO has an effect on leuko-
cyte adhesion and recruitment to sites of infection. NO has also 
been reported to have a direct effect on a variety of organisms by 
directly inhibiting the growth of some viruses, bacteria, parasites, 
and fungi (37).
As previously stated, ventilator-induced lung injury results 
in an increase in systemic inflammatory mediators (biotrauma). 
With the above understanding of the many ways, NO can affect 
immune regulation and the potential impact of iNO in ARDS 
is intriguing. Kinsella et  al. looked at the effects of iNO on 
pulmonary hemodynamics, gas exchange, pulmonary edema, 
and lung myeloperoxidase (MPO) activity, as a marker of lung 
neutrophil accumulation in extremely premature lambs (38). 
They studied lambs exposed to iNO and compared them to con-
trols. They found that the lambs exposed to iNO had improved 
gas exchange but did not have an increase in their lung weight 
or permeability to albumin after several hours of mechanical 
ventilation. They also found that the iNO exposed lambs had 
a reduction in the MPO activity by 79%. They concluded that 
low dose iNO can augment pulmonary blood flow without 
worsening pulmonary edema and can decrease lung neutrophil 
accumulation, which may reduce lung injury. These findings 
support iNO’s properties as both a pulmonary vasodilator and 
immune modulator.
In 2000, The Clinical Inhaled Nitric Oxide Research Group 
(CINRGI) showed that low-dose iNO therapy for PPHN of the 
newborn could decrease the need for ECMO in these neonates 
(5). Additionally, this study showed that the group that received 
low dose iNO also had less chronic lung disease when compared 
to controls. This work was followed by Schreiber et al. who also 
demonstrated that treatment with iNO decreased the incidence 
of chronic lung disease and death among preterm infants with 
respiratory distress syndrome (6). The finding that chronic lung 
disease is decreased with the use of iNO, suggests that the benefit 
of iNO likely extends beyond just pulmonary vasodilation. As 
chronic lung disease is caused at least in part by irritation and 
inflammation of the neonatal lungs, the impact of the use of iNO 
may be a result of iNO’s effect on the immune response to lung 
injury.
ARDS AND iNO iN ADULTS
As mentioned above, the use of iNO for adult patients with 
ARDS began in 1993 when Rossaint et  al. showed improved 
oxygenation in this patient population (22). Subsequent studies 
would also show that oxygenation was improved when iNO was 
used in adult patients with ARDS but demonstrated that there 
was no decrease in morbidity and mortality. The lack of survival 
benefit then called into question the true advantage of using iNO, 
especially given that in some adults iNO use may increase renal 
impairment (3, 39).
A number of systematic reviews with meta-analysis have since 
been conducted to try to answer the question of whether iNO 
reduces mortality in patients with ARDS. These meta-analysis 
have looked at available randomized control trials (RCTs) in 
which there were data on iNO use, ARDS and mortality. In 
2007, Adhikari published his first systemic review of 12 RCTs 
that met inclusion criteria which included a total of 1237 patient 
with ARDS (1). Of the RCTs included two of them were done 
with the pediatric population and accounted for only 132 of 
the total number of patients. The authors of this review found 
no significant effect of iNO on hospital mortality or number 
of ventilator-free days. They concluded that iNO had a short 
lived improvement on oxygenation that conferred no survival 
benefit. In 2014, Adhikari et al. updated their previous search 
and analyzed the data from the systemic review to determine 
if a survival benefit with iNO use could be demonstrated when 
the patients with ARDS were divided into severe versus mild-
moderate ARDS (2). This review had 9 RCTs and 1142 patients 
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that met inclusion criteria. In this review, there were no RCTs 
with only pediatric patients and only one study that included 
pediatric patients of which there were only three children. The 
conclusion from this review was that iNO does not reduce 
mortality in adults and children with ARDS, regardless of the 
degree of hypoxemia. Additionally, it should be noted, that many 
of these trials used a wide range of iNO levels, several of them 
using 5–10 ppm.
In 2011, Afshari et al. also undertook a systemic review with 
meta analysis in which they included 14 RCTs with 1303 patients 
(3). This review included three pediatric studies with a total of 
164 pediatric patients. Ten of the studies had a high risk of bias. 
These authors found no statistically significant effect of iNO on 
duration of ventilation, ventilator-free days, or on length of stay 
in the intensive care unit and hospital. They also concluded that 
iNO results in a transient improvement in oxygenation but does 
not reduce mortality and may be harmful as it increases the risk 
of renal impairment in adults.
ARDS AND iNO iN PeDiATRiCS
To date, there are no published systemic reviews with meta 
analysis comprised exclusively of pediatric RCTs investigating the 
effect of iNO on PARDS. This is not surprising since the findings 
from the aforementioned systemic reviews reveal a very limited 
number of eligible pediatric RCTs on the topic. Of those pediatric 
RCTs that were included, individually they were small in number 
with study designs that limit the ability to draw conclusions on 
how iNO impacts the outcome of PARDS.
By including such a small number of pediatric patients in the 
above systematic reviews with such a larger number of adult stud-
ies and much larger number of adult patients it: (1) may diminish 
the impact and true findings from the pediatric studies and (2) 
allows the authors to apply conclusions generated largely by adult 
data to both adult and pediatric patients which may not be valid.
Of the three pediatric RCTs in the aforementioned systemic 
reviews, only one study was multi-centered which included 7 
centers and 108 pediatric patients (40). This multi-center study 
was a double-blinded, randomized, placebo-controlled trial, 
which looked at oxygenation as an end-point. The study allowed 
for cross-over of the placebo group with treatment failure, which 
made assessment of other endpoints (mortality, duration of 
ventilation) difficult. The results from this study showed that 
iNO improved oxygenation at 12 and 24  h, but by 72  h, there 
was no difference in oxygenation. Interestingly, immunocompro-
mised patients and those patients with more severe oxygenation 
impairment appeared to have a more sustained improvement in 
oxygenation.
The other two pediatric RCTs were single-centered studies. The 
study by Day et al. included 24 pediatric patients and also allowed 
for cross-over of the placebo group with treatment failure again 
making a conclusion on outcome differences impossible (41). The 
third study was conducted by Ibrahim and El-Mohamady and 
they collected data on 32 pediatric patients for only 24 h to assess 
the outcome on oxygenation, they did not collect data on other 
outcomes (42).
The first RCT to evaluate outcomes other than oxygenation in 
patients with PARDS that received iNO was published in 2014 
(43). In this study, Bronicki et al. enrolled 55 pediatric patients in 
a prospective, randomized placebo-controlled trial that showed 
a significant reduction in duration of mechanical ventilation and 
a significantly greater rate of ECMO-free survival. There was a 
trend toward improved overall 28-day survival that did not meet 
statistical significance. There was a significant improvement in 
the oxygenation index of those patient receiving iNO at 12  h, 
but no difference between the oxygenation index of both groups 
at 24  h. An important feature of this study is that it suggests 
that there were benefits to the pediatric patients that received 
iNO, which did not correlate to a sustained improvement in 
oxygenation.
The Pediatric Acute Lung Injury Consensus Conference Group 
was formed in 2012 to better establish the definition for pediatric 
ARDS and to provide recommendations for management. Their 
first consensus recommendations for were published in 2015 
(44), and the following was their recommendation specifically 
about iNO and PARDS:
“Inhaled nitric oxide is not recommended for routine 
use in PARDS. However, its use may be considered in 
patients with documented pulmonary hypertension or 
severe right ventricular dysfunction. In addition, it may 
be considered in severe cases of PARDS as a rescue from 
or bridge to extracorporeal life support. When used, 
assessment of benefit must be undertaken promptly and 
serially to minimize toxicity and to eliminate continued 
use without established effect. Finally, future study is 
needed to better define its role, if any, in the treatment 
of PARDS.” The Group was in strong agreement about 
this recommendation.
The recommendations by the group indicate that iNO may by 
considered for severe ARDS but ultimately that more data needs 
to be collected to understand its role in pediatric ARDS.
wHeRe DO we GO FROM HeRe?
Santschi et  al. illustrated that there is wide practice variability 
in the management in PARDS (45). In the discussion of their 
paper, they estimated that in order to conduct an international 
clinical trial to assess a reduction in mortality in PARDS that it 
would take 60 PICUs and about 4 years to recruit the 800 patients 
needed. Additionally, RCTs call for the limitation of co-founders 
that would force us to individually investigate every aspect of 
management as it pertains to PARDS when the reality is that 
most patients receive a combination of therapies. The resources 
it would require to accomplish studies in this fashion are not 
realistic.
With the challenges of using mortality as an outcome measure 
in pediatric trials, perhaps alternative outcome metrics in PARDS 
should be considered and evaluated such as a health related 
quality of life metric validated in pediatrics, the PedsQLTM Scale 
(46). As it pertains to the impact of iNO in particular, perhaps we 
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should be looking at how it impacts the Pediatric Multiple Organ 
Dysfunction Score (P-MODS) (47). As previously stated, ARDS 
is often not present in isolation and the effects of iNO may spread 
beyond the lungs in a way that could effect the P-MODS, which 
could potentially have an additional impact on the PedsQLTM 
scale.
But likely the most important pursuit is the path toward 
personalized and precision medicine, an emerging reality with 
the rapid evolution of genomic medicine. Although ARDS is a 
disease state with a common histology and pathophysiology, the 
exact manifestation and the response to therapies, such as iNO, 
are likely much more individualized than we will ever gather from 
studying the population as a whole with our tradition approaches. 
Wong and colleagues have done important work in the field of 
genomics and septic shock (48). Among his groups, important 
contributions are the ability for subclass stratification that identi-
fies high risk patients with septic shock based on inflammatory 
response and genomic profiling. This identification has already 
been shown to allow for therapy-related clinical decision making 
particularly as it applies to the use of corticosteroids in septic 
shock (49). Wong and colleagues have demonstrated a path for 
similar work that could be done to link individual genomics with 
ARDS. This could allow for a stratification scheme to identify 
individuals whose genetic profile might benefit from iNO therapy 
and the discovery of the true impact of iNO in ARDS might truly 
be realized. This might prove to be the most worthwhile endeavor 
to truly understand the impact of iNO.
CONCLUSiON
As we continue to strive to improve our management of ARDS, 
it is important to acknowledge that although the disease may 
look similar from patient to patient that it is likely not the same 
disease in everyone. The pathology, the pathophysiology and the 
response to therapy may be quite varied not just by the age of 
the patient but by other individual characteristics of the patients 
as well. So although the RCTs and the systemic reviews of iNO 
and ARDS have helped to guide the management in adults, we 
should be cautious about extrapolating that data to all patients 
with ARDS. Perhaps further exploring the impact of iNO on 
inflammation, coagulation, and applying genomics will provide 
further insight to the very varied disease of ARDS and the patient 
populations that are effected by it. The story of iNO, a molecule 
whose discovery was only within the past 30 years, is still young.
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